Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	1	of	1	Attorney Docket Number	5941-65-PUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.[1]	Document Number Number-kind Code [2 (if known)]	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]; Number[4]; Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	1	WO 2004/030625	04/15/04	BRISTOL-MYERS SQUIBB COMPANY		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No.[1]	
	2	CHRISTENSEN et al. "High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo," Clinical Cancer Research, Dec. 2001, Vol. 7, No. 12, pages 4230-4238
	3	HIRASHIMA et al. "Protein Overexpression and Gene Amplification of c-erb B-2 in Pulmonary Carcinomas: A Comparative Immunohistochemical and Fluorescence In Situ Hybridization Study," Modern Pathology, Jun. 2001, Vol. 14, No. 6, pages 556-562
	4	NAKAMURA et al. "Correlation Between Encoded Protein Overexpression And Copy Number Of The Her2 Gene With Survival In Non-Small Cell Lung Cancer," International Journal of Cancer, Jan. 01, 2003, Vol. 103, No. 1, pages 61-66
	5	TESTA eta l. "Chromosome Abnormalities in Human Non-Small Cell Lung Cancer," Cancer Research, May 01, 1992, Vol. 52, 9 Supplemental, pages 2702s-2706s

Examiner Signature	/Sean Aeder/ (06/09/2011)	Date Considered	

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.A./